# STAGE 12D: VERIFIER D — PEER COVERAGE AUDIT — QUALITEK

Run date: 2026-09-26 | Model: claude-sonnet-5 | Phase 1

Inputs: 12 peer transcripts (VIMTALABS x4, METROPOLIS x4, KRSNAA x4), B06 report
(outputs/reports/06-peers.md, REWORK CYCLE 1), B05-concall.yaml peer_questions[] (6 items).

Note: B06 in hand is already a post-rework (cycle 1) report, carrying its own
REWORK LOG addressing 9 prior verifier findings (attributed to B12b/B12d in that
log). This audit is an independent fresh read against the transcripts; it does not
assume the prior corrections are right, and re-checks the underlying quotes itself.

## PART 1: COVERAGE AUDIT TABLE (per peer, SUBSTANTIVE claims)

| Peer / call | B06 claimed citation | Located in transcript? | Verdict |
|---|---|---|---|
| KRSNAA Nov-2025 | "receivable currently stands around 150 days" (l.304 cited) | Confirmed, l.304, exact wording | CONFIRMED |
| KRSNAA Feb-2026 | Qualitative DSO language only, no day-count repeated (l.424 cited: "days of outstanding moving down") | Confirmed, l.424, exact wording; grepped for 150/155/139-day figures in this file, none found | CONFIRMED (B06's own correction, that no day-count appears here, holds) |
| KRSNAA May-2026 | "139 days... against 155 days in the previous quarter"; "sub 120 days" FY27 guide | Confirmed, l.379/495/497/500 ("reduced our DSO from 155 days... to 139 days"; "against 155 days in the previous quarter"; "sub 120 days guided for FY '27") | CONFIRMED |
| KRSNAA Aug-2026 | RPL breakeven "~1 year," "confident of becoming EBITDA positive by Q2" | Confirmed, l.541 ("confident of becoming EBITDA positive by Q2"), l.776 ("breakeven positive for the entire RPL") | CONFIRMED |
| METROPOLIS Feb-2026 | Core Diagnostics margin trajectory, GST/pricing, genomics positioning | Spot-checked GST/pricing themes present; "negative 2% EBITDA" specific quote is NOT in this file (it is correctly attributed by B06 to the May-2026 call, not Feb-2026) | CONFIRMED — no misattribution found |
| METROPOLIS May-2026 | "committed that within 4 quarters... negative 2% EBITDA to a high-single-digit EBITDA... completed this mission" | Confirmed, l.279-283, exact wording | CONFIRMED |
| METROPOLIS Aug-2026 | "less than 2x revenue"; "effective acquisition multiple would be approximately 10x EBITDA" | Confirmed, l.359/365 | CONFIRMED |
| METROPOLIS Sep-2026 (Investor Meet) | "$11 billion... $28.5 billion... 11% CAGR"; "less than 6% of Indians have ever been diagnosed"; "<2x revenue/10x EBITDA" line explicitly said to be ABSENT here | TAM figures confirmed, l.365/367/378 (exact numbers). Grepped this file for the "2x revenue"/"10x EBITDA" strings: no matches, confirming B06's claim that this quote is NOT in this transcript | CONFIRMED, including the negative claim (quote correctly kept out of this row) |
| VIMTALABS Nov-2025 | "growth rates of all these sectors is around 7.5% to around 9%" (Samir Palod exchange) | Confirmed, l.794/796/808 | CONFIRMED |
| VIMTALABS Feb-2026 | "our majority of business comes from defense" | Confirmed, l.884 | CONFIRMED |
| VIMTALABS May-2026 | "Impact of war is there on us. The cost of some input materials, consumables has gone up slightly..." | Confirmed, l.470 | CONFIRMED |
| VIMTALABS May-2026 | TAM figures "USD9.7 billion" pharma analytical testing, "USD300 million" India analytical testing | Confirmed, l.604/636 | CONFIRMED |
| VIMTALABS Jul-2026 | "growth rates are about 4.5%"; "ran out of capacity in the first three and a half years" | Confirmed, l.1211/1217 | CONFIRMED |

Result: every SUBSTANTIVE citation spot-checked (13 of the ~14 distinct load-bearing
quotes across the 12-transcript coverage map) is genuinely findable at or very near
the cited location, with correct wording. No fabricated or unfindable citation located.
Coverage was not exhaustive line-by-line for every minor supporting figure in Part 2
(capex numbers, TAM breakdowns) given time bounds, but every quote carrying a verdict
(Q1-Q6) or a coverage-map "key contribution" cell that could plausibly be wrong was checked.

**Rule 2 finding: 0 SUBSTANTIVE-without-real-citation cases found across all 12 peers.**

## PART 2: UNUSED / CITED-ONLY SPOT CHECK

B06 marks all 12 of 12 transcripts SUBSTANTIVE; none UNUSED or CITED-ONLY. This audit
spot-read for material the pipeline should have used but did not:
- Searched all 12 transcripts for "related party" / "independent valuer" / "fairness
  opinion": zero matches anywhere. This independently confirms B06's Q2 "Peers silent"
  claim (no peer transcript contains a related-party acquisition discussion at all,
  so there is genuinely nothing comparable to have missed).
- Searched for "attrition": found in VIMTALABS Feb-2026 (l.840/843, cited by B06) and
  VIMTALABS May-2026 (l.222, NOT cited by B06's 2E bullet, which cites only the Feb-2026
  quote), and one incidental mention in METROPOLIS Aug-2026 (l.1043, a question about
  headcount growth vs attrition, not substantively discussed, not cited by B06).
  The missed May-2026 Vimta line is industry-context reinforcement of an already-made
  point (attrition is industry-wide), not a new fact; the Metropolis line is a passing
  question, not management disclosure. Neither rises above MINOR.

**Rule 3 finding: 1 MINOR (VIMTALABS May-2026 attrition line, l.222, not cited
alongside the Feb-2026 attrition quote already used for the same point — an
industry-context reinforcement miss, not a claim-relevant miss).**

## PART 3: VERDICT-DISCIPLINE AUDIT

| Claim | B06 verdict | Independent peer anchors actually present | Discipline check |
|---|---|---|---|
| Q1 (debtor days) | PARTIALLY VERIFIED | 1 peer (Krsnaa, across 4 quarters of the same mechanism) | CORRECT per rule 4 — a VERIFIED resting on one peer must be PARTIALLY VERIFIED; B06 already applies this |
| Q2 (related-party disclosure norm) | CONTRADICTED | Inference from absence + Metropolis disclosure bar (1 direct peer, explicitly labelled as inference from absence of a matching precedent) | CORRECT — not claimed VERIFIED, appropriately hedged |
| Q3 (new-lab margin trajectory) | VERIFIED | 3 peers (Metropolis, Krsnaa, Vimta) each giving a concrete trajectory | CORRECT — genuinely ≥2 independent anchors |
| Q4 (industry growth rate) | VERIFIED | 2 peers (Vimta, Metropolis) citing distinct quantified figures | CORRECT — ≥2 independent anchors |
| Q5 (guidance walk-down acknowledgment) | CONTRADICTED | 2 peers (Vimta, Krsnaa) both acknowledging misses on-call | CORRECT |
| Q6 (input-cost trend) | PARTIALLY VERIFIED | 3 peers, directional only, magnitude not comparable | CORRECT — properly hedged, not overclaimed |

No verdict in B06 is upgraded from silence (a claim where no peer commented, marked
CONTRADICTED or VERIFIED regardless). Every CONTRADICTED verdict is grounded in an
actual peer statement or a stated absence-of-precedent inference, correctly labelled
as such.

**Rule 4 finding: 0 discipline violations. The one apparent risk (Q1, single-peer
VERIFIED) was already self-corrected in B06's own rework cycle to PARTIALLY VERIFIED,
and this audit confirms that correction is right.**

## PART 4: PEER_QUESTIONS COMPLETENESS CHECK

B05-concall.yaml peer_questions[] contains 6 questions (debtor days; related-party
disclosure; margin trajectory of new labs; industry growth rate; guidance walk-down
acknowledgment; raw-material/input-cost trend). B06 Part 1 addresses each as Q1-Q6 in
the same order, each with a verdict. All 6 of 6 addressed.

**Rule 5 finding: 0 skipped claims.**

## SUMMARY

This B06 report (already a rework-cycle-1 output) holds up well against an
independent fresh read of the 12 transcripts. All spot-checked citations are
genuine and accurately quoted. Verdict discipline (the ≥2-independent-peer rule
for VERIFIED) is correctly applied, including the one place it bites (Q1). No
peer is under-used to a MAJOR degree; one MINOR industry-context reinforcement
citation (a second Vimta attrition mention) was available but not used. All 6
peer_questions received verdicts.

```yaml
stage: B12d
company: "QUALITEK"
run_date: "2026-09-26"
model: claude-sonnet-5
status: complete
peers_audited: 12
substantive_confirmed: 12
substantive_unsupported: []
unused_but_relevant:
  - {peer: "VIMTALABS May-2026", missed_item: "second attrition mention (\"talent availability and attrition remain industry-wide challenges\") not cited alongside the Feb-2026 attrition quote already used for the same point; industry-context reinforcement only, not a new fact", anchor: "VIMTALABS-Concall_May_2026_Transcript.txt l.222"}
claims_all_addressed: true
verdict_discipline_fails: []
findings:
  - {severity: "MINOR", location: "B06 Part 2E / attrition bullet", claimed: "attrition risk parity discussed only via Vimta Feb-2026 quote", source_truth: "a second, later Vimta attrition mention exists (May-2026, l.222) making the same point; not cited", note: "reinforcement miss, not a new claim-relevant fact; no verdict changes", source_fidelity: false}
critical_count: 0
major_count: 0
minor_count: 1
acceptance_rate: 100
```
